Your browser is no longer supported. Please, upgrade your browser.
CYCN Cyclerion Therapeutics, Inc. monthly Stock Chart
Cyclerion Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.97 Insider Own1.00% Shs Outstand32.10M Perf Week5.65%
Market Cap102.59M Forward P/E- EPS next Y-0.28 Insider Trans54.60% Shs Float28.88M Perf Month10.74%
Income-84.60M PEG- EPS next Q-0.19 Inst Own71.90% Short Float2.70% Perf Quarter-50.50%
Sales3.60M P/S28.50 EPS this Y-6.80% Inst Trans26.99% Short Ratio1.40 Perf Half Y-30.30%
Book/sh2.35 P/B1.27 EPS next Y83.50% ROA-57.80% Target Price4.00 Perf Year40.38%
Cash/sh1.95 P/C1.54 EPS next 5Y- ROE-105.50% 52W Range1.78 - 8.96 Perf YTD9.93%
Dividend- P/FCF- EPS past 5Y- ROI-128.00% 52W High-64.84% Beta-
Dividend %- Quick Ratio4.30 Sales past 5Y- Gross Margin- 52W Low76.97% ATR0.22
Employees94 Current Ratio4.30 Sales Q/Q-71.40% Oper. Margin- RSI (14)48.72 Volatility7.13% 7.04%
OptionableYes Debt/Eq0.05 EPS Q/Q41.10% Profit Margin- Rel Volume1.54 Prev Close2.99
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume556.26K Price3.15
Recom3.00 SMA2023.02% SMA50-31.34% SMA200-29.62% Volume641,973 Change5.35%
Jun-03-19Initiated Credit Suisse Neutral
Nov-15-20 07:55AM  
Nov-05-20 07:00AM  
Oct-14-20 01:09PM  
Oct-04-20 09:52AM  
Sep-04-20 07:00AM  
Aug-25-20 07:00AM  
Aug-20-20 11:01AM  
Aug-03-20 09:25AM  
Jul-30-20 09:00AM  
Jul-17-20 07:00AM  
Jul-06-20 03:17PM  
Jul-05-20 02:45PM  
Jun-18-20 04:01PM  
May-22-20 07:52AM  
Apr-10-20 07:00AM  
Mar-23-20 06:50AM  
Jan-13-20 07:00AM  
Jan-12-20 05:05PM  
Dec-24-19 08:17AM  
Dec-23-19 07:00AM  
Dec-12-19 03:43PM  
Nov-27-19 07:00AM  
Nov-01-19 10:52AM  
Oct-31-19 08:08AM  
Oct-30-19 09:24AM  
Oct-08-19 08:00AM  
Sep-25-19 01:22PM  
Sep-10-19 08:00AM  
Aug-12-19 08:00AM  
Jul-31-19 10:58AM  
Jul-24-19 03:23PM  
Jun-11-19 08:30AM  
Jun-05-19 09:50AM  
Jun-04-19 01:58PM  
May-13-19 07:00AM  
Apr-25-19 08:00AM  
Apr-09-19 05:37AM  
Apr-02-19 08:00AM  
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Busch AndreasChief Innovation OfficerNov 09Buy2.53125,000316,250254,704Nov 12 05:05 PM
Huyett WilliamChief Financial OfficerNov 06Sale2.523,8279,64467,590Nov 10 07:07 PM
Huyett WilliamChief Financial OfficerFeb 21Sale5.123,55918,22271,417Feb 25 04:11 PM
Currie Mark GPresidentDec 30Sale2.4825,00062,000271,755Dec 31 05:55 PM
Currie Mark GPresidentDec 27Sale2.5525,00063,750296,755Dec 31 05:55 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.